Skip to content
PharmAlert — Clinical Decision Support

WHO IT'S FOR

Different settings, the same question: is this safe for this patient?

Choose a setting to see the kind of prescription PharmAlert would be checking there, and what it would raise.

See a check for your setting

Post-operative patient, 82, nine medicines

CriticalPA-INT-002

Clarithromycin + Simvastatin

Clarithromycin inhibits CYP3A4, raising simvastatin exposure several-fold. Risk of myopathy and rhabdomyolysis.

SuggestedSuspend the statin for the antibiotic course, or use azithromycin — confirm against local formulary.

CriticalPA-INT-008

Warfarin + Macrolide

Macrolides inhibit warfarin metabolism and disturb gut flora that contribute to vitamin K. INR can rise sharply within days.

SuggestedCheck INR within three to five days of starting and again after the course — confirm against local anticoagulation guidance.

WarningPA-INT-020

ACE inhibitor + Potassium-sparing diuretic

Both raise serum potassium. Risk of hyperkalaemia, increased where renal function is already reduced.

SuggestedThe combination is often clinically intended in heart failure. Check U&Es at baseline and one to two weeks after any change.

6 risks · 2 critical

Demonstration only, using fictional patients. Not for clinical use.

Where PharmAlert fits

HOSPITALS
A second check at the point of prescribing, alongside existing ePMA systems.
PRIMARY CARE
Support for repeat prescribing and structured medication review.
COMMUNITY PHARMACIES
Dispensing-stage safety checks with the patient's clinical context attached.
PRIVATE HEALTHCARE
A consistent medication safety standard applied across sites and clinicians.
UNIVERSITIES
A teaching and research environment for clinical pharmacology and prescribing safety.
MINISTRIES OF HEALTH
Population-level medication safety programmes and national prescribing governance.

Tell us where you prescribe.

We will come back with what a pilot would look like for your setting.

Request a pilot